SEC Form 4 · accession 0001209191-16-122457
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Aselage
Officer — Chief Executive Officer · Director
Period of report
May 19, 2016
Accepted (ET)
May 23, 2016 · 1:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee stock option (right to buy)F1 | $16.23 | May 19, 2016 | A | 160,000 | A | — | May 18, 2026 | Common Stock | 160,000 | 160,000 | D |
Explanation of responses
- F1The option vests and becomes exercisable in twelve equal quarterly installments from the date of grant.